Neurocrine Interest Income from 2010 to 2025

NBIX Stock

USD 116.14 0.54 0.47%

Neurocrine Biosciences Interest Income yearly trend continues to be fairly stable with very little volatility. Interest Income is likely to outpace its year average in 2025. Interest Income is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. View All Fundamentals

Interest Income

First Reported

2010-12-31

Previous Quarter

91 M

Current Value

95.5 M

Quarterly Volatility

31.6 M

Credit Downgrade

Yuan Drop

Covid

Check Neurocrine Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurocrine Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 28.5 M, Interest Expense of 7.4 M or Selling General Administrative of 1.1 B, as well as many indicators such as Price To Sales Ratio of 5.53, Dividend Yield of 0.0 or PTB Ratio of 6.06. Neurocrine financial statements analysis is a perfect complement when working with Neurocrine Biosciences Valuation or Volatility modules.

Check out the analysis of Neurocrine Biosciences Correlation against competitors.

For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.

Latest Neurocrine Biosciences' Interest Income Growth Pattern

Below is the plot of the Interest Income of Neurocrine Biosciences over the last few years. It is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. Neurocrine Biosciences' Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurocrine Biosciences' overall financial position and show how it may be relating to other accounts over time.

Interest Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Interest Income

Timeline

Neurocrine Interest Income Regression Statistics

	Arithmetic Mean	20,008,500
	Geometric Mean	6,854,439
	Coefficient Of Variation	157.73
	Mean Deviation	23,132,125
	Median	4,100,000
	Standard Deviation	31,559,153
	Sample Variance	996T
	Range	93.6M
	R-Value	0.72
	Mean Square Error	516.5T
	R-Squared	0.52
	Significance	0
	Slope	4,761,688
	Total Sum of Squares	14939.7T

Neurocrine Interest Income History

	2025	95.5 M
	2024	91 M
	2023	52.8 M
	2020	4.1 M
	2019	25.7 M
	2018	15.1 M
	2017	13.3 M

Other Fundumenentals of Neurocrine Biosciences

Net Interest Income

Neurocrine Biosciences Interest Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Short Term Investments	Long Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Long Term Debt Total	Net Invested Capital	Short Long Term Debt	Net Working Capital	Capital Stock
Total Assets		0.99	0.47	0.62	0.99	0.98	0.97	0.99	0.58	0.87	0.94	0.77	0.58	0.89	0.83	0.96	0.83	0.54	0.98	-0.8	0.74	-0.73	0.83	0.92
Total Stockholder Equity	0.99		0.42	0.67	0.98	0.99	0.93	0.97	0.54	0.86	0.92	0.7	0.55	0.86	0.86	0.98	0.8	0.5	0.97	-0.84	0.73	-0.72	0.86	0.93
Net Debt	0.47	0.42		0.13	0.5	0.47	0.56	0.49	0.76	0.22	0.48	0.6	0.25	0.48	0.41	0.32	0.44	0.34	0.55	0.05	0.23	-0.24	0.14	0.28
Retained Earnings	0.62	0.67	0.13		0.67	0.7	0.48	0.54	0.18	0.57	0.45	0.13	-0.14	0.46	0.75	0.64	0.24	0.26	0.6	-0.74	0.52	-0.38	0.67	0.71
Accounts Payable	0.99	0.98	0.5	0.67		0.99	0.95	0.97	0.65	0.85	0.92	0.72	0.52	0.88	0.84	0.93	0.79	0.53	0.97	-0.76	0.75	-0.66	0.8	0.89
Net Receivables	0.98	0.99	0.47	0.7	0.99		0.92	0.97	0.59	0.84	0.92	0.67	0.51	0.85	0.9	0.96	0.77	0.49	0.95	-0.8	0.69	-0.68	0.84	0.91
Total Liab	0.97	0.93	0.56	0.48	0.95	0.92		0.97	0.66	0.84	0.94	0.89	0.61	0.92	0.72	0.89	0.86	0.61	0.96	-0.68	0.73	-0.73	0.74	0.85
Total Current Assets	0.99	0.97	0.49	0.54	0.97	0.97	0.97		0.62	0.87	0.97	0.82	0.64	0.92	0.81	0.96	0.88	0.58	0.95	-0.75	0.66	-0.76	0.82	0.88
Short Term Debt	0.58	0.54	0.76	0.18	0.65	0.59	0.66	0.62		0.4	0.68	0.65	0.38	0.6	0.42	0.41	0.55	0.43	0.58	-0.08	0.33	-0.17	0.18	0.42
Intangible Assets	0.87	0.86	0.22	0.57	0.85	0.84	0.84	0.87	0.4		0.81	0.68	0.52	0.91	0.66	0.9	0.75	0.66	0.8	-0.79	0.62	-0.79	0.8	0.83
Short Term Investments	0.94	0.92	0.48	0.45	0.92	0.92	0.94	0.97	0.68	0.81		0.82	0.66	0.89	0.75	0.89	0.87	0.6	0.88	-0.66	0.61	-0.75	0.76	0.81
Long Term Debt	0.77	0.7	0.6	0.13	0.72	0.67	0.89	0.82	0.65	0.68	0.82		0.65	0.85	0.43	0.68	0.84	0.64	0.76	-0.4	0.49	-0.69	0.52	0.6
Common Stock	0.58	0.55	0.25	-0.14	0.52	0.51	0.61	0.64	0.38	0.52	0.66	0.65		0.61	0.3	0.59	0.88	0.46	0.55	-0.33	0.48	-0.57	0.54	0.51
Property Plant Equipment	0.89	0.86	0.48	0.46	0.88	0.85	0.92	0.92	0.6	0.91	0.89	0.85	0.61		0.6	0.88	0.88	0.71	0.85	-0.62	0.61	-0.8	0.72	0.77
Current Deferred Revenue	0.83	0.86	0.41	0.75	0.84	0.9	0.72	0.81	0.42	0.66	0.75	0.43	0.3	0.6		0.83	0.55	0.29	0.8	-0.75	0.48	-0.55	0.81	0.79
Net Tangible Assets	0.96	0.98	0.32	0.64	0.93	0.96	0.89	0.96	0.41	0.9	0.89	0.68	0.59	0.88	0.83		0.82	0.5	0.92	-0.88	0.66	-0.79	0.9	0.92
Capital Surpluse	0.83	0.8	0.44	0.24	0.79	0.77	0.86	0.88	0.55	0.75	0.87	0.84	0.88	0.88	0.55	0.82		0.66	0.8	-0.54	0.63	-0.74	0.74	0.74
Deferred Long Term Liab	0.54	0.5	0.34	0.26	0.53	0.49	0.61	0.58	0.43	0.66	0.6	0.64	0.46	0.71	0.29	0.5	0.66		0.49	-0.28	0.47	-0.61	0.51	0.49
Long Term Investments	0.98	0.97	0.55	0.6	0.97	0.95	0.96	0.95	0.58	0.8	0.88	0.76	0.55	0.85	0.8	0.92	0.8	0.49		-0.74	0.79	-0.68	0.78	0.87
Long Term Debt Total	-0.8	-0.84	0.05	-0.74	-0.76	-0.8	-0.68	-0.75	-0.08	-0.79	-0.66	-0.4	-0.33	-0.62	-0.75	-0.88	-0.54	-0.28	-0.74		-0.6	0.63	-0.86	-0.89
Net Invested Capital	0.74	0.73	0.23	0.52	0.75	0.69	0.73	0.66	0.33	0.62	0.61	0.49	0.48	0.61	0.48	0.66	0.63	0.47	0.79	-0.6		-0.53	0.68	0.75
Short Long Term Debt	-0.73	-0.72	-0.24	-0.38	-0.66	-0.68	-0.73	-0.76	-0.17	-0.79	-0.75	-0.69	-0.57	-0.8	-0.55	-0.79	-0.74	-0.61	-0.68	0.63	-0.53		-0.82	-0.68
Net Working Capital	0.83	0.86	0.14	0.67	0.8	0.84	0.74	0.82	0.18	0.8	0.76	0.52	0.54	0.72	0.81	0.9	0.74	0.51	0.78	-0.86	0.68	-0.82		0.89
Capital Stock	0.92	0.93	0.28	0.71	0.89	0.91	0.85	0.88	0.42	0.83	0.81	0.6	0.51	0.77	0.79	0.92	0.74	0.49	0.87	-0.89	0.75	-0.68	0.89

Click cells to compare fundamentals

About Neurocrine Biosciences Financial Statements

Neurocrine Biosciences investors use historical fundamental indicators, such as Neurocrine Biosciences' Interest Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Neurocrine Biosciences. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Interest Income	91 M	95.5 M
Net Interest Income	91 M	95.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Neurocrine Stock Analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Neurocrine Interest Income from 2010 to 2025

Latest Neurocrine Biosciences' Interest Income Growth Pattern

Neurocrine Interest Income Regression Statistics

Neurocrine Interest Income History

Other Fundumenentals of Neurocrine Biosciences

Neurocrine Biosciences Interest Income component correlations

About Neurocrine Biosciences Financial Statements

Also Currently Popular

Additional Tools for Neurocrine Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY